NCM · Biotechnology

BCAB (BCAB) Stock

$1.74 +0.00% NCM: BCAB Healthcare

Valuation

MetricValue
Price$1.74
Market Cap$2.88M
P/E Ratio-0.12
P/B Ratio-0.14
P/S Ratio0.61
EPS (TTM)$-50.50
52-Week High$71.50
52-Week Low$1.74
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE89.25%
ROA-330.89%
ROCE274.64%
Gross Margin-2950.00%
Operating Margin-2950.00%
Net Margin-370.05%
Debt/Equity-0.16
Current Ratio0.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$11.0M$2.0M
Operating Profit$-96.0M$-108.0M$-130.0M$-74.0M$-59.0M
Net Profit$-95.0M$-105.0M$-123.0M$-70.0M$-60.0M
EPS$-138.00$-137.00$-129.00$-72.00$-50.50
Op Margin-38576.0%——-672.2%-2965.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$254.0M$226.0M$120.0M$52.0M$14.0M
Total Liabilities$44.0M$45.0M$49.0M$38.0M$50.0M
Cash$245.0M$216.0M$111.0M$49.0M$7.0M
Borrowings$5.0M$4.0M$2.0M$1.0M$6.0M

Latest News

Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal MT Newswires · May 18, 2026 Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-62.0M$-90.0M$-104.0M$-72.0M$-48.0M
Investing Cash Flow$-2.0M$-1.0M$0$0$0
Financing Cash Flow$-2.0M$0$0$0$-1.0M
Net Cash Flow$6.0M$-29.0M$-104.0M$-62.0M$-42.0M
Free Cash Flow$-63.0M$-91.0M$-104.0M$-72.0M$-48.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.33
FCF Yield-453.51%
Quick Ratio0.20
Interest Coverage—
Return 1Y-78.38%
Return 3Y-96.84%
Return 5Y-99.78%

Ownership

Insiders Held5.46%
Institutions Held22.50%
Institutions Float Held23.80%
Institutional HolderSharesReport Date
Marshall Wace LLP277,6302026-03-31
Acorn Capital Advisors, LLC 108,1272026-03-31
Millennium Management Llc55,1332026-03-31
Vanguard Capital Management LLC32,9852026-03-31
Acadian Asset Management. LLC24,6782026-03-31

About BCAB

BCAB is led by CEO Jay Short, employs 61 people, headquartered in US, publicly traded since 2020.

BCAB stock trades at $1.74 with a market capitalization of $2.88M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.12, reflecting a net loss over the last twelve months, a negative price-to-book of -0.14, reflecting negative shareholders' equity, price-to-sales of 0.61. Over the past 52 weeks the stock has ranged between $1.74 and $71.50, and currently trades 97.6% below its 52-week high.

On profitability, BCAB generates a return on equity (ROE) of 89.25% (not meaningful, as shareholders' equity is negative), return on capital employed of 274.64%, an operating margin of -2950.00%, a net profit margin of -370.05%.

BCAB by the numbers, 2018–2025

Between 2018 and 2025 BCAB reported revenue of $11.0M rising to $2.0M, a change of -81.8% across 8 years. Compounded, revenue has grown —% a year over five years, —% over three, -81.8% over the last twelve months. Net profit fell to $-60.0M.

Operating margin went from -265.7% in 2018 to -2965.3% in 2025, a fall of 2699.6 percentage points. The most recent net margin is -370.05%. On a trailing twelve-month basis to Jun '26, revenue is $9.0M and net profit $-32.0M.

Borrowings fell from $15.0M to $6.0M, cash from operations was $-48.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -122.0% over five years, and was 166.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BCAB (BCAB) — frequently asked questions

What is BCAB (BCAB) stock price today?

BCAB (BCAB) is currently trading at $1.74, up 0% today.

What is BCAB P/E ratio?

BCAB's P/E ratio is -0.12. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is BCAB return on equity (ROE)?

BCAB's return on equity (ROE) is 89.25%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is BCAB's market cap?

BCAB has a market capitalization of $2.88M.

Does BCAB pay a dividend?

BCAB is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does BCAB carry?

BCAB has a debt-to-equity ratio of -0.16. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is BCAB's profit margin?

BCAB reports a net profit margin of -370.05% — the share of revenue left after every cost, including tax and interest.

What sector is BCAB in?

BCAB is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is BCAB listed on?

BCAB trades on NCM under the ticker BCAB.

What is BCAB's 52-week range?

Over the last year BCAB has traded between $1.74 and $71.50.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens BCAB currently matches

On the figures above, BCAB passes the filters for 2 of our ready-made screens, among them Penny Stocks, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny StocksNano Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.